Cold chain disruption Jurata focuses on removing cold storage requirements for vaccines and biologics, suggesting a strong fit for cold chain logistics providers, regional distributors, and on-demand manufacturing partners seeking to simplify distribution and reduce spoilage costs.

Room temperature delivery Developing wafer-like mRNA film and needle-free, room-temperature storage and tongue-delivery presents opportunities for partnerships with global health initiatives, NGO procurement programs, and governments aiming to increase vaccine accessibility in remote or resource-limited settings.

Strategic partnerships Active CEPI collaboration and notable grant funding indicate openness to co-development and grant-driven programs; target potential collaborators in public health consortia, vaccine developers, and philanthropic funders seeking innovative delivery platforms.

Early-stage traction Seed funding and a recent $1M joint grant signal scalability potential; sales conversations can focus on early adopter customers in biotech and contract manufacturing organizations looking to de-risk supply chains and accelerate time-to-market with novel formulations.

Smaller company agility With 11-50 employees and active web presence, Jurata can benefit from pilot projects, flexible contract models, and localized regional partnerships; propose lightweight engagement plans, rapid prototyping collaborations, and milestone-based commitments to win initial wins.